ALVO episode 20261005_ALVO_MIDDAY
Public episode JSON embedded as readable text for automated access.
{
"schema_version": "tryding-agent-episode.v1",
"episode_id": "20261005_ALVO_MIDDAY",
"episode_url": "https://trydingday.com/data/agents/v1/episodes/20261005_ALVO_MIDDAY.html",
"public_page_url": "https://trydingday.com/coverage/alvo/2026-10-05/midday/",
"published_at": "2026-10-05T19:09:34.802136Z",
"updated_at": "2026-10-23T22:01:38.540034Z",
"lifecycle": {
"tracking_status": "open",
"active_for_tracking": true,
"stage": "tracking"
},
"instrument": {
"type": "equity",
"symbol": "ALVO",
"exchange": "NASDAQGM",
"name": "Alvotech"
},
"technical_reference": {
"status": "ok",
"reference_price": 6.25,
"model_downside_reference": 5.66,
"model_upside_scenario_1": 6.83,
"model_upside_scenario_2": 7.42,
"atr_14": 0.39,
"method": "reference_price_plus_minus_atr14"
},
"public_content": {
"date": "October 5, 2026",
"generated_at": "2026-10-05T19:09:34.802136Z",
"original_published_at": null,
"session_tag": "midday",
"label": "Market coverage",
"try_label": "Raw Try",
"public_status": "Raw Try",
"why_today": "Raw Try: ALVO. FDA approval for added SIMLANDI manufacturing capacity gives us a specific question to track: does that capacity enter U.S. commercial supply? The review data does not establish sales, and the captured tape weakened. The model context also carries a wide adverse tail and limited SEC-aware feature coverage. This is a research thesis, not a claim that the 15-session path is established.",
"entry_reasoning": "Panel thesis: FDA approval for added U.S. manufacturing capacity for SIMLANDI creates a testable supply thesis: subsequent company evidence can show whether that capacity enters U.S. commercial supply. The review data does not establish sales or a durable 15-session path. Invalidation boundary: The thesis is materially weakened if company evidence does not show the added capacity entering U.S. commercial supply, or if subsequent regular-session observations show continued relative deterioration versus XLV.",
"reference_price": 6.25,
"scanner": {
"price": 6.25,
"reference": 6.25,
"score": 5,
"score_version": "v0_legacy_reconstructed",
"change": 14.59,
"volume": 1868973,
"average_volume": 993060,
"volume_ratio": 1.88,
"rsi": 70.2,
"ema_trend": "5.8 > 5.56 > 4.97",
"position_52w": 68.99,
"atr_14": 0.39,
"vwap": 6.25,
"vwap_state": "below",
"vwap_distance_pct": 0.0,
"vwap_reading": {
"price": 6.25,
"state": "below",
"distance_pct": 0.0
},
"range_position": 0.54,
"gap_pct": 0.0,
"relative_strength": {
"excess_pct": 14.09,
"index": "QQQ",
"index_chg_pct": 0.5,
"status": "normal"
},
"volume_percentile": {
"median_vol": 728000,
"percentile": 92.2,
"status": "exceptional",
"today_vol": 1868973
},
"extension": {
"atr": 0.39,
"dist_atr": 1.76,
"ema_ref": 5.56,
"status": "healthy"
},
"atr_move_signal": {
"atr_pct": 6.24,
"status": "strong",
"z": 2.34
},
"sector_breadth": {
"chg_pct": -0.1,
"etf": "XLV",
"status": "neutral"
},
"sentiment": null,
"sentiment_score": null,
"earnings_warning": {
"days_away": null,
"earnings_date": null,
"has_earnings_soon": false,
"status": "clear"
},
"options_snapshot": null,
"extended_hours": {
"ext_pct": null,
"market_state": "REGULAR",
"phase": "regular",
"post_market_pct": null,
"pre_market_pct": null,
"status": "none"
},
"coiled_spring": {
"component_count": 0,
"components": {},
"count": 0,
"detector_version": "coiled-compression-ohlc.v1",
"reason": "coiled_ohlc_detector_runs_on_research_and_known_ticker_rails",
"schema_version": "coiled-features.v2",
"status": "not_evaluated"
},
"short_pct_float": 3.61,
"days_to_cover": 5.8,
"catalyst": "Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site",
"sector": "Healthcare",
"exchange": "NasdaqGM",
"sec_signal": "NO_RECENT_FORM4_SIGNAL"
},
"levels": {
"reference": 6.25,
"downside": 5.66,
"upside_1": 6.83,
"upside_2": 7.42
},
"review": {
"score": 5,
"status": "Raw Try",
"summary": "Raw Try: ALVO. FDA approval for added SIMLANDI manufacturing capacity gives us a specific question to track: does that capacity enter U.S. commercial supply? The sealed evidence does not establish sales, and the captured tape weakened. The model context also carries a wide adverse tail and limited SEC-aware feature coverage. This is a research thesis, not a claim that the 15-session path is established.",
"views": [
{
"name": "Elena Vartanyan",
"role": "independent statistical auditor",
"icon": "🎯",
"view": "The broad indexes were positive, but the day was not one-way. Rates and the dollar were firmer, volatility edged higher, and the commodity picture was mixed. That is useful context; it does not make any issuer’s thesis.",
"reasoning": "Adverse-MAE means the model’s estimate of the worst interim loss from entry, not the return at the end of the period."
},
{
"name": "Marcus Feld",
"role": "information, fundamentals and catalyst analyst",
"icon": "🦊",
"view": "The IEA’s $3.4 trillion investment projection points to a large energy buildout, while the sealed ECB headline stresses energy’s inflation pass-through. Those are different forces. And the IEA page is dated May 28, so it is background, not new October news.",
"reasoning": "I still support Raw Try because the next company update can answer that supply question and the thesis has a clear falsifier. The auditor’s correction changes the public comparison scope, not that decision."
},
{
"name": "Kenji Osei",
"role": "AI Systems & Market Data Integrity Analyst",
"icon": "🧠",
"view": "The supplied market snapshot was complete when captured. The breadth measure—the count of names advancing versus declining—came from a separate intraday sample and leaned positive; its end-of-day layer was unavailable. We should keep that time boundary visible.",
"reasoning": "Keep the alternatives distinct: VST has an expected financing story, RRGB a completed refinancing with terms still missing, PCVX a reported trial result with a weak captured finish, and LLY a label expansion with little volume response."
},
{
"name": "Priya Nandakumar",
"role": "institutional risk and execution manager",
"icon": "🛡️",
"view": "A constructive market can help a lot of stocks at once. Higher financing costs and lower WTI can still cut the other way for energy-sensitive names. No one gets an issuer-specific thesis as a free gift from the backdrop.",
"reasoning": "My Caught dissent remains. The supply test is useful, but until commercial entry is shown, the event and weaker tape do not establish a publishable 15-session path."
},
{
"name": "Nate Brooks",
"role": "market structure and timing analyst",
"icon": "📈",
"view": "Then the question is which packet has a business event that can survive its own tape. ALVO has the cleanest specific event in the group: the packet records FDA approval for added SIMLANDI manufacturing capacity.",
"reasoning": "The model’s 46.40% H15 output is only context: it is a live initial observation with no trajectory sessions. Its adverse-MAE range has a wide downside tail and only 9 of 23 SEC-aware features."
}
],
"conviction": {
"status_phrase": "recorded",
"basis": "The Auditor found the Raw Try decision defensible and the ALVO thesis testable. Confidence remains bounded by unproven commercial impact, weaker captured tape, model downside uncertainty, and the substantive Caught dissent. These percentages express decision confidence, not a model forecast or vote count.",
"risk": "",
"resolution_pct": 65.0,
"counter_case_pct": 25.0,
"unresolved_pct": 10.0
},
"context_roundtable": {
"mode": "coffee",
"status": "complete",
"consulted_voice_ids": [
"elena",
"marcus",
"kenji",
"priya",
"nate"
],
"summary": "The day combined firm major equity benchmarks with higher Treasury yields and a firmer dollar. Oil eased in the captured market snapshot, while IEA reporting described recovering crude exports alongside continuing refined-product constraints. The intraday breadth proxy leaned positive, but it preceded the later market snapshot and its end-of-day layer was unavailable. These readings describe the backdrop; they do not establish an issuer-level cause or commercial outcome for ALVO.",
"long_read": "The sealed market snapshot was captured at 2026-10-05T16:54:40.710669Z and marked complete across seven rows. The S&P 500 changed by +0.63%, the Nasdaq 100 by +0.66%, and the Russell 2000 by +0.63%. The VIX level was 15.51, with a reported change of +1.31%. The U.S. 10-year yield level was 5.334%, with a reported change of +5.70 basis points; DXY was 102.244, with a reported change of +0.31%. Gold and WTI were shown at $4,158.50 and $90.04, with changes of −0.09% and −1.17%, respectively. These are captured levels and changes, not a claim about the later close.\n\nA separate Reuters report on October 5 described record-setting U.S. equities alongside firmer Treasury yields and the dollar, while oil prices eased. The IEA’s October 2 energy-security update described recovery in crude exports from the Middle East while refined-product flows, including diesel, remained constrained. That distinction matters: crude supply and the availability of processed fuels are different parts of the energy chain. The IEA’s May 28 projection of $3.4 trillion in global energy investment for 2026 is an annual projection, not a one-day investment change or an October 5 issuer catalyst.\n\nThe intraday breadth proxy was captured at 2026-10-05T16:35:20.600958Z and had complete fresh-quote coverage for its sample. It leaned positive, which suggests the gains were shared across more names in that sample; it is not the same observation as the later market snapshot. The end-of-day breadth layer was unavailable. The snapshot itself preceded the recovery cutoff by about 26 minutes. Together, these sources provide a complete, bounded account of the material day context while leaving the later close and end-of-day breadth unresolved. Nothing in this context establishes a causal link to Alvotech’s capacity event or proves entry into U.S. commercial supply.",
"transcript": [
{
"speaker_id": "elena",
"text": "The sealed market snapshot at 16:54Z shows the S&P 500 up 0.63%, the Nasdaq 100 up 0.66%, and the Russell 2000 up 0.63%. The broad benchmarks were firm in that captured window."
},
{
"speaker_id": "marcus",
"text": "Reuters also reported record-setting U.S. equities, with Treasury yields and the dollar firmer while oil eased. Its report is an earlier view of the session, so it complements the snapshot rather than sharing its exact capture time."
},
{
"speaker_id": "kenji",
"text": "Keep the yield’s level separate from its move: it was 5.334%, with a reported increase of 5.70 basis points. One basis point is 0.01 percentage point, so that change is 0.057 percentage point, not a 5.70% yield."
},
{
"speaker_id": "priya",
"text": "The VIX level was 15.51 and its reported change was +1.31%. The supplied read describes volatility as contained, but the increase still shows that a firm equity session did not mean every risk measure moved in the same direction."
},
{
"speaker_id": "nate",
"text": "Breadth means how widely a market move is shared across stocks. The earlier intraday proxy leaned positive with complete fresh-quote coverage in its sample, but its end-of-day layer was unavailable, so it cannot tell us how the whole session finished."
},
{
"speaker_id": "elena",
"text": "The commodity row is mixed: gold was at $4,158.50 with a −0.09% change, and WTI was at $90.04 with a −1.17% change. The dollar figures are levels; the percentages are the reported moves."
},
{
"speaker_id": "marcus",
"text": "The IEA’s October 2 update adds an energy-supply distinction: crude exports had recovered, while refined products such as diesel remained constrained. Different stages of the supply chain can have different conditions."
},
{
"speaker_id": "kenji",
"text": "So easing crude prices do not by themselves establish that fuel supply is fully normal. The IEA item describes separate flows; it does not show that either one caused a particular company’s share move."
},
{
"speaker_id": "priya",
"text": "The IEA’s $3.4 trillion figure is its projection for total global energy investment in 2026, published in May. It is an annual forecast, not money invested that day or a fresh October 5 trigger.",
"source_urls": [
"https://www.iea.org/news/impacts-of-middle-east-conflict-set-to-reshape-energy-investment-plans-as-disruptions-put-focus-on-security"
]
},
{
"speaker_id": "nate",
"text": "That distinction keeps the energy story in its proper place. For Alvotech, the sealed case asks whether added capacity enters U.S. commercial supply; these broad energy sources do not answer that company-specific question."
},
{
"speaker_id": "elena",
"text": "The snapshot was complete when captured, but it was about 26 minutes before the recovery cutoff. It is a useful session reading, not a closing-market record."
},
{
"speaker_id": "marcus",
"text": "The combination is more informative than a single headline: equity benchmarks advanced while yields and the dollar also strengthened, and the energy evidence remained mixed across crude and refined products."
},
{
"speaker_id": "kenji",
"text": "The sources answer different questions: the sealed market rows give levels and changes at their capture time; the IEA gives an energy-flow update; Reuters reports the broader session. None supplies a company-level causal bridge to Alvotech."
},
{
"speaker_id": "priya",
"text": "That leaves a clear day-level picture: firm equity benchmarks with rate, currency, and energy crosscurrents. The broader setting helps readers place the publication, while commercial supply still needs company-specific evidence."
}
],
"source_urls": [
"https://www.iea.org/news/impacts-of-middle-east-conflict-set-to-reshape-energy-investment-plans-as-disruptions-put-focus-on-security"
]
},
"context_roundtable_sources": [
{
"event_id": null,
"headline": "IEA projects $3.4 trillion in global energy investment in 2026",
"url": "https://www.iea.org/news/impacts-of-middle-east-conflict-set-to-reshape-energy-investment-plans-as-disruptions-put-focus-on-security",
"publisher": "International Energy Agency",
"source_quality": "primary",
"public_safe": true,
"published_at": null,
"available_at": null
}
]
},
"updates": [
{
"day": 14,
"timestamp": "2026-10-23T22:01:38.540034Z",
"date": "Session 14 · Oct 23, 2026 · 18:01 NASDAQGM",
"text": "The tracked loss widened 0.08 points to 26.72% on session 14, with the latest capture near $4.58 below its $4.66 session average on 0.61 times usual volume. Added SIMLANDI capacity remains a manufacturing step rather than evidence of U.S. commercial supply; the 20-session lag to Healthcare has widened to 25.38 points.",
"price": 4.58,
"pct": -26.72,
"return_vs_entry_pct": -26.72,
"return_vs_base_pct": -26.72,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.08,
"session_day": 14,
"reference_price": 6.25,
"reference_text": "$4.58 · -26.72% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-23T20:01:27Z",
"vwap_as_of": null
},
{
"day": 14,
"timestamp": "2026-10-23T19:53:17.209361Z",
"date": "Session 14 · Oct 23, 2026 · 15:53 NASDAQGM",
"text": "On session 14, the tracked ALVO loss widened another 0.96 points to 26.64%, with shares down 4.49% to $4.58 below the session average on 0.45 times usual volume; its 20-session lag to Healthcare is 25.32 points. FDA approval for added SIMLANDI capacity remains a real manufacturing step, but the packet still shows no U.S. commercial supply, while the worsening relative record further weakens the market side of the thesis.",
"price": 4.575,
"pct": -26.64,
"return_vs_entry_pct": -26.8,
"return_vs_base_pct": -26.8,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -2.32,
"session_day": 14,
"reference_price": 6.25,
"reference_text": "$4.58 · -26.80% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": true,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-cdee7982ee1ccbc3966b3bfeb11649ccc6231b0302bbcd72e1cba449268163b0",
"price_as_of": "2026-10-23T19:22:12.987963Z",
"vwap_as_of": null
},
{
"day": 14,
"timestamp": "2026-10-23T14:55:57.805437Z",
"date": "Session 14 · Oct 23, 2026 · 10:55 NASDAQGM",
"text": "ALVO's tracked loss widened another 2.32 points to 25.68% on session 14 as shares slipped to $4.72 below the session average on light activity. Its 20-session lag versus Healthcare narrowed to 23.22 points, but the handoff still shows no evidence that added SIMLANDI capacity has entered U.S. commercial supply, leaving the thesis unconfirmed.",
"price": 4.72,
"pct": -25.68,
"return_vs_entry_pct": -24.48,
"return_vs_base_pct": -24.48,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.12,
"session_day": 14,
"reference_price": 6.25,
"reference_text": "$4.72 · -24.48% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-23T14:06:04.621810Z",
"vwap_as_of": null
},
{
"day": 13,
"timestamp": "2026-10-22T22:04:24.148456Z",
"date": "Session 13 · Oct 22, 2026 · 18:04 NASDAQGM",
"text": "The tracked loss widened 0.64 points to 23.36% on session 13; shares fell 6.63% to $4.79 below VWAP on 0.84 times average volume. The 20-session return trails Healthcare by 25.27 points, and the prepared record still does not show SIMLANDI entering U.S. commercial supply, so the added-capacity thesis remains unconfirmed.",
"price": 4.79,
"pct": -23.36,
"return_vs_entry_pct": -23.36,
"return_vs_base_pct": -23.36,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.48,
"session_day": 13,
"reference_price": 6.25,
"reference_text": "$4.79 · -23.36% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-22T20:23:11Z",
"vwap_as_of": null
},
{
"day": 13,
"timestamp": "2026-10-22T19:35:28.462052Z",
"date": "Session 13 · Oct 22, 2026 · 15:35 NASDAQGM",
"text": "Alvotech says FDA approval of a new SIMLANDI process more than doubles output per batch and frees capacity for other products, but available evidence still does not show SIMLANDI entering U.S. commercial supply. On session 13, ALVO's tracked loss widened 4.80 percentage points to 22.72%, and its 20-session return lagged Healthcare by 24.81 points; the latest capture fell 6.04% near the session low on 0.67 times usual volume. The model's 48.4% continuation estimate and near-flat median across the remaining two sessions are nearly neutral and do not explain the worsening relative record.",
"price": 4.82,
"pct": -22.72,
"return_vs_entry_pct": -22.88,
"return_vs_base_pct": -22.88,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -4.96,
"session_day": 13,
"reference_price": 6.25,
"reference_text": "$4.82 · -22.88% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-b0068ebf34d9ccef3ade9b6821b624002bc9208e19a404f51ac737f92ec43ecb",
"price_as_of": "2026-10-22T19:21:50.306215Z",
"vwap_as_of": null
},
{
"day": 12,
"timestamp": "2026-10-21T21:52:26.689306Z",
"date": "Session 12 · Oct 21, 2026 · 17:52 NASDAQGM",
"text": "ALVO eased its tracked loss by 0.16 points to -17.92% on session 12. Shares were up 0.20% to $5.13 but remained below VWAP near the lower range. The stock still trails Healthcare by 17.71 points over twenty sessions, with distribution in the flow measure; this small bounce does not show that added SIMLANDI capacity is entering U.S. supply.",
"price": 5.13,
"pct": -17.92,
"return_vs_entry_pct": -17.92,
"return_vs_base_pct": -17.92,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.16,
"session_day": 12,
"reference_price": 6.25,
"reference_text": "$5.13 · -17.92% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-21T20:01:37Z",
"vwap_as_of": null
},
{
"day": 12,
"timestamp": "2026-10-21T00:35:47.988281Z",
"date": "Session 12 · Oct 20, 2026 · 20:35 NASDAQGM",
"text": "ALVO's tracked loss held at 18.08% on session 12 while the quote rose 1.79% to $5.12 on 1.18 times average volume. It remained 2.27% below VWAP and trails Healthcare by 18.39 points over 20 sessions, with no confirmed price structure; the bounce does not yet show that added SIMLANDI manufacturing capacity is reaching U.S. supply.",
"price": 5.12,
"pct": -18.08,
"return_vs_entry_pct": -18.08,
"return_vs_base_pct": -18.08,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.08,
"session_day": 12,
"reference_price": 6.25,
"reference_text": "$5.12 · -18.08% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-20T21:44:11Z",
"vwap_as_of": null
},
{
"day": 11,
"timestamp": "2026-10-20T23:09:40.217030Z",
"date": "Session 11 · Oct 20, 2026 · 19:09 NASDAQGM",
"text": "ALVO tracked loss narrowed 1.44 points to 18.08% as shares rose 1.89% to $5.13, but finished 2.27% below VWAP near the session low. The stock still trails Healthcare by 17.78 points over 20 sessions, so this bounce is weak price repair and does not show that added SIMLANDI capacity has entered U.S. supply.",
"price": 5.125,
"pct": -18.08,
"return_vs_entry_pct": -18.0,
"return_vs_base_pct": -18.0,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 1.52,
"session_day": 11,
"reference_price": 6.25,
"reference_text": "$5.12 · -18.00% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-20T19:32:17.054310Z",
"vwap_as_of": null
},
{
"day": 10,
"timestamp": "2026-10-19T22:18:42.737912Z",
"date": "Session 10 · Oct 19, 2026 · 18:18 NASDAQGM",
"text": "ALVO's tracked loss widened 1.36 percentage points to 19.52%, even as shares edged 0.60% higher and held 0.38% above VWAP on 0.83 times average volume. It still trails Healthcare by 18.39 points over 20 sessions, so this small rebound does not show the added SIMLANDI capacity entering U.S. supply.",
"price": 5.03,
"pct": -19.52,
"return_vs_entry_pct": -19.52,
"return_vs_base_pct": -19.52,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.36,
"session_day": 10,
"reference_price": 6.25,
"reference_text": "$5.03 · -19.52% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-19T20:01:35Z",
"vwap_as_of": null
},
{
"day": 10,
"timestamp": "2026-10-19T20:01:23.798325Z",
"date": "Session 10 · Oct 19, 2026 · 16:01 NASDAQGM",
"text": "ALVO's tracked loss narrowed 1.84 points to 18.16% as the quote rose 2.30% and moved 0.29% above VWAP, but volume was 0.46 times normal and the price remains about one ATR below its 21-day average. It still trails Healthcare by 17.18 points over 20 sessions; the added SIMLANDI capacity has not been shown entering US supply, so the rebound alone does not confirm the thesis.",
"price": 5.115,
"pct": -18.16,
"return_vs_entry_pct": -18.16,
"return_vs_base_pct": -18.16,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 1.84,
"session_day": 10,
"reference_price": 6.25,
"reference_text": "$5.12 · -18.16% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-19T19:21:30.182691Z",
"vwap_as_of": null
},
{
"day": 9,
"timestamp": "2026-10-16T22:05:48.128979Z",
"date": "Session 9 · Oct 16, 2026 · 18:05 NASDAQGM",
"text": "ALVO's tracked loss widened 0.32 points to 20.00% after another 5.84% decline toward the range low, with distribution still visible over 20 sessions. The stock now trails Healthcare by 19.76 points; until company evidence shows SIMLANDI capacity entering U.S. supply or sales, the capacity thesis remains unconfirmed and the market case continues to deteriorate.",
"price": 5.0,
"pct": -20.0,
"return_vs_entry_pct": -20.0,
"return_vs_base_pct": -20.0,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.32,
"session_day": 9,
"reference_price": 6.25,
"reference_text": "$5.00 · -20.00% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-16T20:00:13Z",
"vwap_as_of": null
},
{
"day": 9,
"timestamp": "2026-10-16T20:10:29.234467Z",
"date": "Session 9 · Oct 16, 2026 · 16:10 NASDAQGM",
"text": "ALVO tracked loss widened 1.76 points to 19.68%; the latest quote fell 5.46%, sat 1.10% below the volume-weighted average near the range low, and traded at 0.75x normal volume. It now trails Healthcare by 19.37 points over 20 sessions, while added SIMLANDI capacity still has no verified entry into U.S. commercial supply or sales.",
"price": 5.02,
"pct": -19.68,
"return_vs_entry_pct": -19.68,
"return_vs_base_pct": -19.68,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.92,
"session_day": 9,
"reference_price": 6.25,
"reference_text": "$5.02 · -19.68% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-16T19:21:22.647785Z",
"vwap_as_of": null
},
{
"day": 9,
"timestamp": "2026-10-16T14:22:44.863836Z",
"date": "Session 9 · Oct 16, 2026 · 10:22 NASDAQGM",
"text": "ALVO's tracked loss widened 2.88 points to 17.92%; the latest quote fell 3.20%, 1.01% below VWAP near the session low. It now trails Healthcare by 17.90 points over 20 sessions, reinforcing the deterioration; the FDA-approved added SIMLANDI capacity still has no verified entry into U.S. commercial supply or sales.",
"price": 5.14,
"pct": -17.92,
"return_vs_entry_pct": -17.76,
"return_vs_base_pct": -17.76,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -2.72,
"session_day": 9,
"reference_price": 6.25,
"reference_text": "$5.14 · -17.76% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-16T14:06:07.820265Z",
"vwap_as_of": null
},
{
"day": 8,
"timestamp": "2026-10-15T22:11:17.887017Z",
"date": "Session 8 · Oct 15, 2026 · 18:11 NASDAQGM",
"text": "ALVO's tracked loss widened 0.40 percentage points to 15.04%, while the latest quote still showed a 2.71% day gain on 1.08 times average volume. That is a partial tape repair, but the key check—whether the added manufacturing capacity enters U.S. commercial supply and produces sales—remains unverified. The price move has not supplied operating confirmation.",
"price": 5.31,
"pct": -15.04,
"return_vs_entry_pct": -15.04,
"return_vs_base_pct": -15.04,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.56,
"session_day": 8,
"reference_price": 6.25,
"reference_text": "$5.31 · -15.04% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-15T20:01:27Z",
"vwap_as_of": null
},
{
"day": 8,
"timestamp": "2026-10-15T20:17:15.069037Z",
"date": "Session 8 · Oct 15, 2026 · 16:17 NASDAQGM",
"text": "ALVO's tracked loss narrowed 2.48 points to 14.64%; shares rose 3.38%, held 0.71% above VWAP near the upper end. The 20-session return still trails Healthcare by 5.59 points, and the current evidence does not show the added SIMLANDI manufacturing capacity entering U.S. supply. This is an intraday repair, not operating confirmation.",
"price": 5.345,
"pct": -14.64,
"return_vs_entry_pct": -14.48,
"return_vs_base_pct": -14.48,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 1.68,
"session_day": 8,
"reference_price": 6.25,
"reference_text": "$5.34 · -14.48% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-15T19:21:33.629030Z",
"vwap_as_of": null
},
{
"day": 8,
"timestamp": "2026-10-15T15:34:12.328857Z",
"date": "Session 8 · Oct 15, 2026 · 11:34 NASDAQGM",
"text": "ALVO's tracked loss narrowed 0.16 points to 17.12%; shares rose 1.35% and stood 0.36% above VWAP near the upper end of the range. Yet it still trails Healthcare by 7.44 points over 20 sessions, on only 7% of average dollar turnover, and the prepared evidence shows no commercial entry for the approved SIMLANDI capacity.",
"price": 5.24,
"pct": -17.12,
"return_vs_entry_pct": -16.16,
"return_vs_base_pct": -16.16,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 1.12,
"session_day": 8,
"reference_price": 6.25,
"reference_text": "$5.24 · -16.16% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-15T14:06:44.673876Z",
"vwap_as_of": null
},
{
"day": 7,
"timestamp": "2026-10-14T21:43:35.943223Z",
"date": "Session 7 · Oct 14, 2026 · 17:43 NASDAQGM",
"text": "ALVO's tracked loss widened another 0.24 points to 17.28%; shares fell 3.90% in the regular session, reached the low 2.82% below VWAP, then rebounded 1.55% after hours. It still trails XLV by 2.32 points over 20 sessions, a little worse than the prior 1.85-point lag. The approved capacity still has no evidence of commercial entry, leaving the supply test unproven and the market-side weakness in place.",
"price": 5.17,
"pct": -17.28,
"return_vs_entry_pct": -17.28,
"return_vs_base_pct": -17.28,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.16,
"session_day": 7,
"reference_price": 6.25,
"reference_text": "$5.17 · -17.28% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-14T21:09:19Z",
"vwap_as_of": null
},
{
"day": 7,
"timestamp": "2026-10-14T20:06:41.597044Z",
"date": "Session 7 · Oct 14, 2026 · 16:06 NASDAQGM",
"text": "Since the previous note, ALVO's tracked loss widened 1.68 points to 17.04%; the latest capture fell 3.72%, sat 2.63% below VWAP at the session low, and now trails XLV by 1.85 points over 20 sessions. That reverses the prior 2.91-point lead, while the packet still shows no commercial entry for the approved Reykjavik SIMLANDI capacity. The supply test remains unproven and the relative deterioration now materially weakens the thesis.",
"price": 5.18,
"pct": -17.04,
"return_vs_entry_pct": -17.12,
"return_vs_base_pct": -17.12,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -3.52,
"session_day": 7,
"reference_price": 6.25,
"reference_text": "$5.18 · -17.12% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-1de1a1db849bab5c24e6cbe0766f5f5426a60b9ffc5e4ed70c22ee4f352effc6",
"price_as_of": "2026-10-14T19:41:13.876792Z",
"vwap_as_of": null
},
{
"day": 7,
"timestamp": "2026-10-14T15:09:50.938063Z",
"date": "Session 7 · Oct 14, 2026 · 11:09 NASDAQGM",
"text": "For ALVO, the tracked loss widened 1.44 points to 15.36% even as shares rose 0.37% and held just above VWAP at midrange. The 20-session lead over Healthcare is 2.91 points, but the approval still has no shown path into U.S. commercial supply; the capacity question remains unanswered.",
"price": 5.4,
"pct": -15.36,
"return_vs_entry_pct": -13.6,
"return_vs_base_pct": -13.6,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.32,
"session_day": 7,
"reference_price": 6.25,
"reference_text": "$5.40 · -13.60% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-14T14:06:37.850462Z",
"vwap_as_of": null
},
{
"day": 6,
"timestamp": "2026-10-13T21:48:21.961717Z",
"date": "Session 6 · Oct 13, 2026 · 17:48 NASDAQGM",
"text": "ALVO's tracked loss narrowed 0.56 points to 13.92% even as shares fell 2.18%, sat 0.74% below VWAP near the range low, and traded on dollar turnover of 0.83 times its 20-day average. Its 20-session lead over Healthcare narrowed to 5.98 points, while the packet still shows no evidence the approved SIMLANDI capacity has entered U.S. commercial supply.",
"price": 5.38,
"pct": -13.92,
"return_vs_entry_pct": -13.92,
"return_vs_base_pct": -13.92,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.56,
"session_day": 6,
"reference_price": 6.25,
"reference_text": "$5.38 · -13.92% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-13T20:01:27Z",
"vwap_as_of": null
},
{
"day": 6,
"timestamp": "2026-10-13T20:08:13.140028Z",
"date": "Session 6 · Oct 13, 2026 · 16:08 NASDAQGM",
"text": "ALVO’s tracked loss deepened 0.48 points to 14.48% as shares fell 2.82%, below VWAP near the range low, on 0.86 times average volume. The added SIMLANDI capacity still needs a bridge to U.S. commercial supply; today’s renewed pressure leaves that operating question unanswered.",
"price": 5.345,
"pct": -14.48,
"return_vs_entry_pct": -14.48,
"return_vs_base_pct": -14.48,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -2.48,
"session_day": 6,
"reference_price": 6.25,
"reference_text": "$5.34 · -14.48% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-13T19:24:51.998952Z",
"vwap_as_of": null
},
{
"day": 6,
"timestamp": "2026-10-13T15:28:50.206549Z",
"date": "Session 6 · Oct 13, 2026 · 11:28 NASDAQGM",
"text": "ALVO's tracked loss deepened 2.00 percentage points to 14.00% while shares were unchanged at $5.50, 0.90% below the day's volume-weighted average price and at the session low. Its 20-session lead over Healthcare has narrowed to 8.26 points. The renewed pressure weighs on a thesis that still needs evidence the added SIMLANDI capacity is entering U.S. commercial supply.",
"price": 5.5,
"pct": -14.0,
"return_vs_entry_pct": -12.0,
"return_vs_base_pct": -12.0,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.0,
"session_day": 6,
"reference_price": 6.25,
"reference_text": "$5.50 · -12.00% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-13T14:06:26.349567Z",
"vwap_as_of": null
},
{
"day": 5,
"timestamp": "2026-10-12T22:07:49.525775Z",
"date": "Session 5 · Oct 12, 2026 · 18:07 NASDAQGM",
"text": "ALVO's tracked loss widened 0.56 points to 12.00% as shares fell 4.84% to $5.50, ended 1.55% below the volume-weighted average price near the bottom of the range, and traded at 0.80 times average volume. Despite a 6.38-point 20-session lead over Healthcare, no company evidence shows added SIMLANDI capacity entering U.S. commercial supply, so the decline deepens price pressure without testing the supply thesis.",
"price": 5.5,
"pct": -12.0,
"return_vs_entry_pct": -12.0,
"return_vs_base_pct": -12.0,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.16,
"session_day": 5,
"reference_price": 6.25,
"reference_text": "$5.50 · -12.00% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-12T20:01:24Z",
"vwap_as_of": null
},
{
"day": 5,
"timestamp": "2026-10-12T19:45:46.937780Z",
"date": "Session 5 · Oct 12, 2026 · 15:45 NASDAQGM",
"text": "ALVO's tracked loss narrowed 1.04 percentage points to 11.44%, with the price at USD 5.51, 1.55% below its volume-weighted average price and in the lower part of the session range on half its three-month average volume. Its 6.62-point 20-session lead over Healthcare remains, but no supplied evidence shows the added SIMLANDI capacity entering U.S. commercial supply; the supply thesis remains unproven.",
"price": 5.51,
"pct": -11.44,
"return_vs_entry_pct": -11.84,
"return_vs_base_pct": -11.84,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.64,
"session_day": 5,
"reference_price": 6.25,
"reference_text": "$5.51 · -11.84% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-12T19:23:05.083706Z",
"vwap_as_of": null
},
{
"day": 5,
"timestamp": "2026-10-12T19:14:00.968927Z",
"date": "Session 5 · Oct 12, 2026 · 15:14 NASDAQGM",
"text": "ALVO's tracked loss widened 3.04 percentage points to 12.48% as shares fell 5.36% to $5.47, 2.67% below VWAP and at the captured session low. Turnover was 0.43 times its three-month average, while ALVO's 20-session return still leads Healthcare by 5.92 points. The approved Reykjavik capacity remains a supply thesis: this package still shows no evidence it has entered U.S. commercial supply. The model's 46.9% same-down probability through session 15 is near even and comes with a wide range, so the price decline weakens the tape but does not settle the supply test.",
"price": 5.47,
"pct": -12.48,
"return_vs_entry_pct": -12.48,
"return_vs_base_pct": -12.48,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -3.04,
"session_day": 5,
"reference_price": 6.25,
"reference_text": "$5.47 · -12.48% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-9979219058ec99a71c395ab0a6f7c597e0dc785eded8c1611e4fd7b0e84dde07",
"price_as_of": "2026-10-12T18:48:37.209746Z",
"vwap_as_of": null
},
{
"day": 4,
"timestamp": "2026-10-09T14:49:24.562390Z",
"date": "Session 4 · Oct 9, 2026 · 10:49 NASDAQGM",
"text": "ALVO tracked loss widened 0.16 points to 9.44%; the current quote is 0.18% lower and remains 0.35% below VWAP on 0.10 times average volume. Its twenty-session lead over Healthcare remains 4.10 points, but the capture still does not show the added SIMLANDI capacity entering U.S. commercial supply.",
"price": 5.66,
"pct": -9.44,
"return_vs_entry_pct": -9.44,
"return_vs_base_pct": -9.44,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.16,
"session_day": 4,
"reference_price": 6.25,
"reference_text": "$5.66 · -9.44% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-09T14:06:45.252947Z",
"vwap_as_of": null
},
{
"day": 3,
"timestamp": "2026-10-08T21:54:09.411202Z",
"date": "Session 3 · Oct 8, 2026 · 17:54 NASDAQGM",
"text": "ALVO's tracked loss narrowed 0.16 points to 9.28%, while shares fell 3.08% to $5.67 and ended 0.53% below VWAP on 0.64 times average volume. Its 20-session lead over Healthcare is 6.70 points, but the capture still does not show Reykjavik SIMLANDI capacity entering U.S. commercial supply.",
"price": 5.67,
"pct": -9.28,
"return_vs_entry_pct": -9.28,
"return_vs_base_pct": -9.28,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.32,
"session_day": 3,
"reference_price": 6.25,
"reference_text": "$5.67 · -9.28% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-08T20:00:14Z",
"vwap_as_of": null
},
{
"day": 3,
"timestamp": "2026-10-08T19:45:04.885555Z",
"date": "Session 3 · Oct 8, 2026 · 15:45 NASDAQGM",
"text": "ALVO's tracked loss widened another 1.36 points to 9.44% as shares fell 3.42% on 0.43 times average volume and stayed below the session's volume-weighted average price; its twenty-session lead over Healthcare narrowed to 6.47 points. The active model leaves a broad, near-even range, and the packet still does not show Reykjavik SIMLANDI capacity entering U.S. commercial supply.",
"price": 5.65,
"pct": -9.44,
"return_vs_entry_pct": -9.6,
"return_vs_base_pct": -9.6,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -2.16,
"session_day": 3,
"reference_price": 6.25,
"reference_text": "$5.65 · -9.60% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-5ea87e40eafd8e6ec68862df7fa763891a52d265731bf5da114f616fa6102514",
"price_as_of": "2026-10-08T19:22:13.087729Z",
"vwap_as_of": null
},
{
"day": 3,
"timestamp": "2026-10-08T15:02:21.256331Z",
"date": "Session 3 · Oct 8, 2026 · 11:02 NASDAQGM",
"text": "ALVO tracked loss widened 1.68 points to -8.08% as shares fell 1.11% to $5.79 on 0.10 times average volume, just below VWAP. It still leads Healthcare by 10.04 points, but that margin is shrinking; the Syracuse agreement does not show that separate Reykjavik SIMLANDI capacity has entered commercial U.S. supply.",
"price": 5.785,
"pct": -8.08,
"return_vs_entry_pct": -7.44,
"return_vs_base_pct": -7.44,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.04,
"session_day": 3,
"reference_price": 6.25,
"reference_text": "$5.79 · -7.44% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-08T14:06:42.195821Z",
"vwap_as_of": null
},
{
"day": 2,
"timestamp": "2026-10-07T21:52:58.279396Z",
"date": "Session 2 · Oct 7, 2026 · 17:52 NASDAQGM",
"text": "ALVO session-2 tracked loss widened 0.72 points to -6.40% after shares fell 4.72% to the session low on below-average volume. Its 20-session lead over XLV remains positive at 10.94 points, down from 13.38 in the last note. A new LOTTE agreement covers a Syracuse facility and multiple biosimilars, but does not show that the separately approved Reykjavik SIMLANDI capacity has entered U.S. commercial supply.",
"price": 5.85,
"pct": -6.4,
"return_vs_entry_pct": -6.4,
"return_vs_base_pct": -6.4,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -1.12,
"session_day": 2,
"reference_price": 6.25,
"reference_text": "$5.85 · -6.40% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-cc82358117f481633d6b7b274bf21ad4ef50cb418e65300757d0c6e2714171dd",
"price_as_of": "2026-10-07T20:11:43Z",
"vwap_as_of": null
},
{
"day": 2,
"timestamp": "2026-10-07T20:38:32.488197Z",
"date": "Session 2 · Oct 7, 2026 · 16:38 NASDAQGM",
"text": "ALVO's tracked loss widened 1.84 points to -5.68% as shares fell 3.58% to $5.92, below VWAP at the bottom of the range on 0.63 times average volume. It still leads Healthcare by 13.38 points over twenty sessions, but that relative cushion did not prevent a weaker tape today. There is still no evidence that added manufacturing capacity has entered U.S. commercial supply or generated sales.",
"price": 5.92,
"pct": -5.68,
"return_vs_entry_pct": -5.28,
"return_vs_base_pct": -5.28,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -0.8,
"session_day": 2,
"reference_price": 6.25,
"reference_text": "$5.92 · -5.28% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-07T19:21:41.146640Z",
"vwap_as_of": null
},
{
"day": 2,
"timestamp": "2026-10-07T15:10:24.875230Z",
"date": "Session 2 · Oct 7, 2026 · 11:10 NASDAQGM",
"text": "ALVO's tracked loss widened 2.16 points to -3.84%, and its $5.97 capture fell 2.77%, sat 0.26% below the session average near the lower third of the range and came with very light participation. It retains a 13.38-point 20-session lead over Healthcare, but today's deterioration weakens the market response. The added manufacturing capacity still has no prepared evidence of U.S. commercial supply or sales.",
"price": 5.97,
"pct": -3.84,
"return_vs_entry_pct": -4.48,
"return_vs_base_pct": -4.48,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -3.04,
"session_day": 2,
"reference_price": 6.25,
"reference_text": "$5.97 · -4.48% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-07T14:06:33.450164Z",
"vwap_as_of": null
},
{
"day": 1,
"timestamp": "2026-10-06T20:03:39.603849Z",
"date": "Session 1 · Oct 6, 2026 · 16:03 NASDAQGM",
"text": "ALVO's tracked loss narrowed 1.52 points to -1.68%. The $6.16 capture gained 0.82%, held 1.18% above VWAP near the top of its range and had roughly average daily volume, though its 20-session relative lead coexists with negative money flow. The FDA-approved added capacity remains a supply thesis; the prepared evidence still does not show it entering U.S. commercial supply or generating sales.",
"price": 6.16,
"pct": -1.68,
"return_vs_entry_pct": -1.44,
"return_vs_base_pct": -1.44,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.8,
"session_day": 1,
"reference_price": 6.25,
"reference_text": "$6.16 · -1.44% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-06T19:21:35.651397Z",
"vwap_as_of": null
},
{
"day": 1,
"timestamp": "2026-10-06T14:52:57.578006Z",
"date": "Session 1 · Oct 6, 2026 · 10:52 NASDAQGM",
"text": "ALVO's tracked loss widened 0.96 points to 3.20% from yesterday and now sits 3.20 points below the initial panel baseline. The $6.11 capture was flat early and only 0.16% above VWAP; its 17.46-point 20-session lead over Health Care remains intact. The evidence still does not show FDA-approved capacity entering U.S. commercial supply, and the active model leaves a wide, near-even range.",
"price": 6.11,
"pct": -3.2,
"return_vs_entry_pct": -2.24,
"return_vs_base_pct": -2.24,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.0,
"session_day": 1,
"reference_price": 6.25,
"reference_text": "$6.11 · -2.24% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": true,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "transcript-entry-0c15f50aef2c763c7786a1117cfb823bfe1a3a74d66c6b0dd7f1c5a9bce3e326",
"price_as_of": "2026-10-06T14:06:59.842254Z",
"vwap_as_of": null
},
{
"day": 0,
"timestamp": "2026-10-05T22:36:38.172088Z",
"date": "Session 0 · Oct 5, 2026 · 18:36 NASDAQGM",
"text": "ALVO's tracked loss narrowed by 0.08 points to 2.24%. The prepared post-session $6.11 quote was up 12.11% on 2.92 times three-month average volume, but no regular-session bars or VWAP are available to characterize the move. FDA approval of added SIMLANDI manufacturing capacity remains a supply question; the prepared evidence still shows neither sales nor U.S. commercial supply.",
"price": 6.11,
"pct": -2.24,
"return_vs_entry_pct": -2.24,
"return_vs_base_pct": -2.24,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": 0.0,
"session_day": 0,
"reference_price": 6.25,
"reference_text": "$6.11 · -2.24% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-05T21:12:52Z",
"vwap_as_of": null
},
{
"day": 0,
"timestamp": "2026-10-05T20:28:54.882214Z",
"date": "Session 0 · Oct 5, 2026 · 16:28 NASDAQGM",
"text": "ALVO's first tracked reading is a 2.32% loss. No current quote, volume or VWAP evidence is available to characterize the tape. FDA approval for added SIMLANDI manufacturing capacity presents a specific supply question, but the prepared evidence does not show sales or confirm that the capacity has entered U.S. commercial supply.",
"price": 6.11,
"pct": -2.32,
"return_vs_entry_pct": -2.24,
"return_vs_base_pct": -2.24,
"return_vs_prior_pct": null,
"previous_regular_close": null,
"change_vs_prior_session_pct": -2.24,
"session_day": 0,
"reference_price": 6.25,
"reference_text": "$6.11 · -2.24% from $6.25 base",
"timing": "",
"market_marker": null,
"extended_hours": null,
"relevant": false,
"active_relevant": false,
"terminal_closure": false,
"transcript_anchor": "",
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
}
],
"observed_outcomes": [
{
"label": "+1 sessions",
"status": "complete",
"return": -1.76,
"reference_text": "-1.76% from $6.25 base",
"price": 6.14,
"updated": "Oct 6, 2026 · 17:49 NASDAQGM",
"mfe": -1.36,
"mae": -4.0
},
{
"label": "+5 sessions",
"status": "complete",
"return": -12.0,
"reference_text": "-12.00% from $6.25 base",
"price": 5.5,
"updated": "Oct 12, 2026 · 17:37 NASDAQGM",
"mfe": -1.28,
"mae": -12.96
},
{
"label": "+10 sessions",
"status": "complete",
"return": -19.52,
"reference_text": "-19.52% from $6.25 base",
"price": 5.03,
"updated": "Oct 19, 2026 · 17:05 NASDAQGM",
"mfe": -1.28,
"mae": -20.8
},
{
"label": "+15 sessions",
"status": "pending",
"return": null,
"reference_text": "",
"price": null,
"updated": "",
"mfe": null,
"mae": null
}
],
"candidate_comparison_history": [
{
"day": 0,
"timestamp": "2026-10-05T20:28:54.882214Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-05T20:28:54.882214Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 6.11,
"base_price": 6.245,
"return_since_base_pct": -2.1617,
"session_return_pct": 14.59,
"change_since_prior_pct": 0.0819,
"volume_ratio": 1.88,
"rsi": 70.2,
"vwap": 6.25,
"vwap_distance_pct": -2.24,
"position_52w_pct": 68.99,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.8 > 5.56 > 4.97",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 13.9266,
"nasdaq100": 13.7184,
"russell2000": 14.0873
},
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 144.89,
"base_price": 145.0475,
"return_since_base_pct": -0.1086,
"session_return_pct": null,
"change_since_prior_pct": 0.0691,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.3324,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:20:00Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T20:20:00Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": -0.7398,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 73.9,
"base_price": 73.55,
"return_since_base_pct": 0.4759,
"session_return_pct": 0.1084,
"change_since_prior_pct": 0.285,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -7.7288,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:21:46Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -0.555,
"nasdaq100": -0.7632,
"russell2000": -0.3943
},
"price_as_of": "2026-10-05T20:21:46Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1143.93,
"base_price": 1154.4901,
"return_since_base_pct": -0.9147,
"session_return_pct": -0.076,
"change_since_prior_pct": 0.0477,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.71,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:10:57Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.7394,
"nasdaq100": -0.9476,
"russell2000": -0.5787
},
"price_as_of": "2026-10-05T20:10:57Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7773.95,
"base_price": 7722.72,
"return_since_base_pct": 0.6634,
"session_return_pct": 0.6634,
"as_of": "2026-10-05T20:28:24.894538Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31076.441,
"base_price": 30807.932,
"return_since_base_pct": 0.8716,
"session_return_pct": 0.8716,
"as_of": "2026-10-05T20:28:24.894538Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2847.1357,
"base_price": 2832.8948,
"return_since_base_pct": 0.5027,
"session_return_pct": 0.5027,
"as_of": "2026-10-05T20:28:24.894538Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 0,
"timestamp": "2026-10-05T22:36:38.172088Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-05T22:36:38.172088Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 6.14,
"base_price": 6.245,
"return_since_base_pct": -1.6813,
"session_return_pct": 12.11,
"change_since_prior_pct": 0.491,
"volume_ratio": 2.92,
"rsi": 68.86,
"vwap": 6.25,
"vwap_distance_pct": -1.76,
"position_52w_pct": 67.6,
"extended_hours_pct": 0.49,
"as_of": "2026-10-05T21:12:52Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.78 > 5.55 > 4.99",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 11.4466,
"nasdaq100": 11.2384,
"russell2000": 11.6073
},
"price_as_of": "2026-10-05T21:12:52Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.3589,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": -0.3045,
"nasdaq100": -0.5127,
"russell2000": -0.1438
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": -3.843,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.4022,
"nasdaq100": -4.6104,
"russell2000": -4.2415
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.181,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.4115,
"nasdaq100": -0.6197,
"russell2000": -0.2508
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7773.95,
"base_price": 7722.72,
"return_since_base_pct": 0.6634,
"session_return_pct": 0.6634,
"as_of": "2026-10-05T22:30:02.530881Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31076.441,
"base_price": 30807.932,
"return_since_base_pct": 0.8716,
"session_return_pct": 0.8716,
"as_of": "2026-10-05T22:30:02.530881Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2847.1357,
"base_price": 2832.8948,
"return_since_base_pct": 0.5027,
"session_return_pct": 0.5027,
"as_of": "2026-10-05T22:30:02.530881Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 1,
"timestamp": "2026-10-06T14:52:57.578006Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-06T14:52:57.578006Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 6.11,
"base_price": 6.245,
"return_since_base_pct": -2.1617,
"session_return_pct": 0.491,
"change_since_prior_pct": -0.4886,
"volume_ratio": 0.19,
"rsi": 67.97,
"vwap": 6.1,
"vwap_distance_pct": 0.1639,
"position_52w_pct": 67.6,
"extended_hours_pct": null,
"as_of": "2026-10-06T14:06:59.842254Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.84 > 5.6 > 5.03",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": -0.2176,
"nasdaq100": -0.2866,
"russell2000": 0.8627
},
"price_as_of": "2026-10-06T14:06:59.842254Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": -0.3497,
"nasdaq100": -0.4187,
"russell2000": 0.7306
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.4474,
"nasdaq100": -4.5164,
"russell2000": -3.3671
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.4567,
"nasdaq100": -0.5257,
"russell2000": 0.6236
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7829.04,
"base_price": 7773.95,
"return_since_base_pct": 0.7086,
"session_return_pct": 0.7086,
"as_of": "2026-10-06T14:52:29.261557Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31318.086,
"base_price": 31076.441,
"return_since_base_pct": 0.7776,
"session_return_pct": 0.7776,
"as_of": "2026-10-06T14:52:29.261557Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2836.5515,
"base_price": 2847.1357,
"return_since_base_pct": -0.3717,
"session_return_pct": -0.3717,
"as_of": "2026-10-06T14:52:29.261557Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 1,
"timestamp": "2026-10-06T20:03:39.603849Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-06T20:03:39.603849Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 6.16,
"base_price": 6.245,
"return_since_base_pct": -1.3611,
"session_return_pct": 0.82,
"change_since_prior_pct": 0.8183,
"volume_ratio": 0.92,
"rsi": 68.53,
"vwap": 6.09,
"vwap_distance_pct": 1.1494,
"position_52w_pct": 68.1,
"extended_hours_pct": null,
"as_of": "2026-10-06T19:21:35.651397Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.85 > 5.6 > 5.04",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 0.2256,
"nasdaq100": 0.3329,
"russell2000": 1.5343
},
"price_as_of": "2026-10-06T19:21:35.651397Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": -0.2355,
"nasdaq100": -0.1282,
"russell2000": 1.0732
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.3332,
"nasdaq100": -4.2259,
"russell2000": -3.0245
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.3425,
"nasdaq100": -0.2352,
"russell2000": 0.9662
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7820.16,
"base_price": 7773.95,
"return_since_base_pct": 0.5944,
"session_return_pct": 0.5944,
"as_of": "2026-10-06T19:59:33.026072Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31227.828,
"base_price": 31076.441,
"return_since_base_pct": 0.4871,
"session_return_pct": 0.4871,
"as_of": "2026-10-06T19:59:33.026072Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2826.798,
"base_price": 2847.1357,
"return_since_base_pct": -0.7143,
"session_return_pct": -0.7143,
"as_of": "2026-10-06T19:59:33.026072Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 2,
"timestamp": "2026-10-07T15:10:24.875230Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-07T15:10:24.875230Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.97,
"base_price": 6.245,
"return_since_base_pct": -4.4035,
"session_return_pct": -2.77,
"change_since_prior_pct": -3.0844,
"volume_ratio": 0.05,
"rsi": 61.37,
"vwap": 5.99,
"vwap_distance_pct": -0.3339,
"position_52w_pct": 66.0,
"extended_hours_pct": null,
"as_of": "2026-10-07T14:06:33.450164Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.87 > 5.64 > 5.07",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-07T14:06:33.450164Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 2,
"timestamp": "2026-10-07T20:38:32.488197Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-07T20:38:32.488197Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.92,
"base_price": 6.245,
"return_since_base_pct": -5.2042,
"session_return_pct": -3.58,
"change_since_prior_pct": -0.8375,
"volume_ratio": 0.63,
"rsi": 60.28,
"vwap": 6.01,
"vwap_distance_pct": -1.4975,
"position_52w_pct": 65.5,
"extended_hours_pct": null,
"as_of": "2026-10-07T19:21:41.146640Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.86 > 5.63 > 5.07",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": -3.3605,
"nasdaq100": -3.3731,
"russell2000": -2.2694
},
"price_as_of": "2026-10-07T19:21:41.146640Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.5784,
"nasdaq100": 0.5658,
"russell2000": 1.6695
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -3.5193,
"nasdaq100": -3.5319,
"russell2000": -2.4282
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": 0.4714,
"nasdaq100": 0.4588,
"russell2000": 1.5625
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7801.77,
"base_price": 7818.93,
"return_since_base_pct": -0.2195,
"session_return_pct": -0.2195,
"as_of": "2026-10-07T20:30:43.184621Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31160.076,
"base_price": 31224.686,
"return_since_base_pct": -0.2069,
"session_return_pct": -0.2069,
"as_of": "2026-10-07T20:30:43.184621Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2793.204,
"base_price": 2830.2974,
"return_since_base_pct": -1.3106,
"session_return_pct": -1.3106,
"as_of": "2026-10-07T20:30:43.184621Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 2,
"timestamp": "2026-10-07T21:52:58.279396Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-07T21:52:58.279396Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.83,
"base_price": 6.245,
"return_since_base_pct": -6.6453,
"session_return_pct": -4.72,
"change_since_prior_pct": -1.5203,
"volume_ratio": 0.83,
"rsi": 58.82,
"vwap": 6.01,
"vwap_distance_pct": -2.995,
"position_52w_pct": 64.7,
"extended_hours_pct": -0.43,
"as_of": "2026-10-07T20:11:43Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.85 > 5.63 > 5.07",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": -4.5005,
"nasdaq100": -4.5131,
"russell2000": -3.4094
},
"price_as_of": "2026-10-07T20:11:43Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.5784,
"nasdaq100": 0.5658,
"russell2000": 1.6695
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -3.5193,
"nasdaq100": -3.5319,
"russell2000": -2.4282
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": 0.4714,
"nasdaq100": 0.4588,
"russell2000": 1.5625
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7801.77,
"base_price": 7818.93,
"return_since_base_pct": -0.2195,
"session_return_pct": -0.2195,
"as_of": "2026-10-07T21:48:14.576244Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31160.076,
"base_price": 31224.686,
"return_since_base_pct": -0.2069,
"session_return_pct": -0.2069,
"as_of": "2026-10-07T21:48:14.576244Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2793.204,
"base_price": 2830.2974,
"return_since_base_pct": -1.3106,
"session_return_pct": -1.3106,
"as_of": "2026-10-07T21:48:14.576244Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 3,
"timestamp": "2026-10-08T15:02:21.256331Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-08T15:02:21.256331Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.785,
"base_price": 6.245,
"return_since_base_pct": -7.3659,
"session_return_pct": -1.11,
"change_since_prior_pct": -0.7719,
"volume_ratio": 0.1,
"rsi": 48.25,
"vwap": 5.79,
"vwap_distance_pct": -0.0864,
"position_52w_pct": 64.0,
"extended_hours_pct": null,
"as_of": "2026-10-08T14:06:42.195821Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.84 > 5.64 > 5.1",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": -0.8076,
"nasdaq100": -0.6437,
"russell2000": -0.5298
},
"price_as_of": "2026-10-08T14:06:42.195821Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.6613,
"nasdaq100": 0.8252,
"russell2000": 0.9391
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -3.4364,
"nasdaq100": -3.2725,
"russell2000": -3.1586
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": 0.5543,
"nasdaq100": 0.7182,
"russell2000": 0.8321
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7778.18,
"base_price": 7801.77,
"return_since_base_pct": -0.3024,
"session_return_pct": -0.3024,
"as_of": "2026-10-08T14:55:12.664497Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 31014.77,
"base_price": 31160.076,
"return_since_base_pct": -0.4663,
"session_return_pct": -0.4663,
"as_of": "2026-10-08T14:55:12.664497Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2776.999,
"base_price": 2793.204,
"return_since_base_pct": -0.5802,
"session_return_pct": -0.5802,
"as_of": "2026-10-08T14:55:12.664497Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 3,
"timestamp": "2026-10-08T19:45:04.885555Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-08T19:45:04.885555Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.65,
"base_price": 6.245,
"return_since_base_pct": -9.5276,
"session_return_pct": -3.42,
"change_since_prior_pct": -2.3336,
"volume_ratio": 0.43,
"rsi": 45.7,
"vwap": 5.7,
"vwap_distance_pct": -0.8772,
"position_52w_pct": 62.5,
"extended_hours_pct": null,
"as_of": "2026-10-08T19:22:13.087729Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.81 > 5.63 > 5.09",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-08T19:22:13.087729Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 3,
"timestamp": "2026-10-08T21:54:09.411202Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-08T21:54:09.411202Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.67,
"base_price": 6.245,
"return_since_base_pct": -9.2074,
"session_return_pct": -3.08,
"change_since_prior_pct": 0.354,
"volume_ratio": 0.64,
"rsi": 46.06,
"vwap": 5.7,
"vwap_distance_pct": -0.5263,
"position_52w_pct": 62.7,
"extended_hours_pct": 0.0,
"as_of": "2026-10-08T20:00:14Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.81 > 5.63 > 5.09",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-08T20:00:14Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 4,
"timestamp": "2026-10-09T14:49:24.562390Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-09T14:49:24.562390Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.66,
"base_price": 6.245,
"return_since_base_pct": -9.3675,
"session_return_pct": -0.18,
"change_since_prior_pct": -0.1764,
"volume_ratio": 0.1,
"rsi": 45.67,
"vwap": 5.68,
"vwap_distance_pct": -0.3521,
"position_52w_pct": 62.6,
"extended_hours_pct": null,
"as_of": "2026-10-09T14:06:45.252947Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.78 > 5.63 > 5.11",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-09T14:06:45.252947Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 5,
"timestamp": "2026-10-12T19:14:00.968927Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-12T19:14:00.968927Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.47,
"base_price": 6.245,
"return_since_base_pct": -12.4099,
"session_return_pct": -5.36,
"change_since_prior_pct": -3.3569,
"volume_ratio": 0.43,
"rsi": 43.64,
"vwap": 5.62,
"vwap_distance_pct": -2.669,
"position_52w_pct": 60.5,
"extended_hours_pct": null,
"as_of": "2026-10-12T18:48:37.209746Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.74 > 5.63 > 5.13",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-12T18:48:37.209746Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 5,
"timestamp": "2026-10-12T19:45:46.937780Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-12T19:45:46.937780Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.51,
"base_price": 6.245,
"return_since_base_pct": -11.7694,
"session_return_pct": -4.67,
"change_since_prior_pct": 0.7313,
"volume_ratio": 0.5,
"rsi": 44.25,
"vwap": 5.6,
"vwap_distance_pct": -1.6071,
"position_52w_pct": 60.9,
"extended_hours_pct": null,
"as_of": "2026-10-12T19:23:05.083706Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.75 > 5.63 > 5.13",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-12T19:23:05.083706Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 5,
"timestamp": "2026-10-12T22:07:49.525775Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-12T22:07:49.525775Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.5,
"base_price": 6.245,
"return_since_base_pct": -11.9295,
"session_return_pct": -4.84,
"change_since_prior_pct": -0.1815,
"volume_ratio": 0.8,
"rsi": 44.1,
"vwap": 5.6,
"vwap_distance_pct": -1.7857,
"position_52w_pct": 60.8,
"extended_hours_pct": 0.0,
"as_of": "2026-10-12T20:01:24Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.75 > 5.63 > 5.13",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": -4.785,
"nasdaq100": -4.1327,
"russell2000": -4.3946
},
"price_as_of": "2026-10-12T20:01:24Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.4139,
"nasdaq100": 1.0662,
"russell2000": 0.8043
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -3.6838,
"nasdaq100": -3.0315,
"russell2000": -3.2934
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": 0.3069,
"nasdaq100": 0.9592,
"russell2000": 0.6973
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7807.24,
"base_price": 7811.54,
"return_since_base_pct": -0.055,
"session_return_pct": -0.055,
"as_of": "2026-10-12T22:07:30.030818Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 30664.697,
"base_price": 30883.148,
"return_since_base_pct": -0.7073,
"session_return_pct": -0.7073,
"as_of": "2026-10-12T22:07:30.030818Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2794.48,
"base_price": 2806.9814,
"return_since_base_pct": -0.4454,
"session_return_pct": -0.4454,
"as_of": "2026-10-12T22:07:30.030818Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 6,
"timestamp": "2026-10-13T15:28:50.206549Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-13T15:28:50.206549Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.5,
"base_price": 6.245,
"return_since_base_pct": -11.9295,
"session_return_pct": 0.491,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.14,
"rsi": 44.56,
"vwap": 5.55,
"vwap_distance_pct": -0.9009,
"position_52w_pct": 60.8,
"extended_hours_pct": null,
"as_of": "2026-10-13T14:06:26.349567Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.7 > 5.62 > 5.15",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-13T14:06:26.349567Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 6,
"timestamp": "2026-10-13T20:08:13.140028Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-13T20:08:13.140028Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.345,
"base_price": 6.245,
"return_since_base_pct": -14.4115,
"session_return_pct": -2.82,
"change_since_prior_pct": -2.8182,
"volume_ratio": 0.86,
"rsi": 42.26,
"vwap": 5.42,
"vwap_distance_pct": -1.3838,
"position_52w_pct": 59.1,
"extended_hours_pct": null,
"as_of": "2026-10-13T19:24:51.998952Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.67 > 5.6 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-13T19:24:51.998952Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 6,
"timestamp": "2026-10-13T21:48:21.961717Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-13T21:48:21.961717Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.38,
"base_price": 6.245,
"return_since_base_pct": -13.8511,
"session_return_pct": -2.18,
"change_since_prior_pct": 0.6548,
"volume_ratio": 1.15,
"rsi": 42.76,
"vwap": 5.42,
"vwap_distance_pct": -0.738,
"position_52w_pct": 59.5,
"extended_hours_pct": 0.0,
"as_of": "2026-10-13T20:01:27Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.67 > 5.61 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-13T20:01:27Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 7,
"timestamp": "2026-10-14T15:09:50.938063Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-14T15:09:50.938063Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.4,
"base_price": 6.245,
"return_since_base_pct": -13.5308,
"session_return_pct": 0.37,
"change_since_prior_pct": 0.3717,
"volume_ratio": 0.24,
"rsi": 41.78,
"vwap": 5.4,
"vwap_distance_pct": 0.0,
"position_52w_pct": 59.7,
"extended_hours_pct": null,
"as_of": "2026-10-14T14:06:37.850462Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.62 > 5.59 > 5.15",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 1.1537,
"nasdaq100": 1.5635,
"russell2000": 1.6608
},
"price_as_of": "2026-10-14T14:06:37.850462Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 1.1426,
"nasdaq100": 1.5524,
"russell2000": 1.6497
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -2.9551,
"nasdaq100": -2.5453,
"russell2000": -2.448
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": 1.0356,
"nasdaq100": 1.4454,
"russell2000": 1.5427
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7744.28,
"base_price": 7805.45,
"return_since_base_pct": -0.7837,
"session_return_pct": -0.7837,
"as_of": "2026-10-14T15:07:18.695896Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 30204.63,
"base_price": 30569.48,
"return_since_base_pct": -1.1935,
"session_return_pct": -1.1935,
"as_of": "2026-10-14T15:07:18.695896Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2747.4421,
"base_price": 2783.369,
"return_since_base_pct": -1.2908,
"session_return_pct": -1.2908,
"as_of": "2026-10-14T15:07:18.695896Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 7,
"timestamp": "2026-10-14T20:06:41.597044Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-14T20:06:41.597044Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.18,
"base_price": 6.245,
"return_since_base_pct": -17.0536,
"session_return_pct": -3.72,
"change_since_prior_pct": -4.0741,
"volume_ratio": 0.78,
"rsi": 38.71,
"vwap": 5.32,
"vwap_distance_pct": -2.6316,
"position_52w_pct": 57.3,
"extended_hours_pct": null,
"as_of": "2026-10-14T19:41:13.876792Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.57 > 5.57 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-14T19:41:13.876792Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 7,
"timestamp": "2026-10-14T21:43:35.943223Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-14T21:43:35.943223Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.25,
"base_price": 6.245,
"return_since_base_pct": -15.9327,
"session_return_pct": -3.9,
"change_since_prior_pct": 1.3514,
"volume_ratio": 0.97,
"rsi": 38.59,
"vwap": 5.32,
"vwap_distance_pct": -1.3158,
"position_52w_pct": 57.2,
"extended_hours_pct": 1.55,
"as_of": "2026-10-14T21:09:19Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.57 > 5.57 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-14T21:09:19Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 8,
"timestamp": "2026-10-15T15:34:12.328857Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-15T15:34:12.328857Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.24,
"base_price": 6.245,
"return_since_base_pct": -16.0929,
"session_return_pct": 1.35,
"change_since_prior_pct": -0.1905,
"volume_ratio": 0.09,
"rsi": 41.64,
"vwap": 5.22,
"vwap_distance_pct": 0.3831,
"position_52w_pct": 58.2,
"extended_hours_pct": null,
"as_of": "2026-10-15T14:06:44.673876Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.51 > 5.54 > 5.15",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-15T14:06:44.673876Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 8,
"timestamp": "2026-10-15T20:17:15.069037Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-15T20:17:15.069037Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.345,
"base_price": 6.245,
"return_since_base_pct": -14.4115,
"session_return_pct": 3.38,
"change_since_prior_pct": 2.0038,
"volume_ratio": 0.67,
"rsi": 43.58,
"vwap": 5.31,
"vwap_distance_pct": 0.6591,
"position_52w_pct": 59.4,
"extended_hours_pct": null,
"as_of": "2026-10-15T19:21:33.629030Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.53 > 5.55 > 5.15",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 3.0546,
"nasdaq100": 3.4308,
"russell2000": 1.9761
},
"price_as_of": "2026-10-15T19:21:33.629030Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.0335,
"nasdaq100": 0.4097,
"russell2000": -1.045
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.0642,
"nasdaq100": -3.688,
"russell2000": -5.1427
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.0735,
"nasdaq100": 0.3027,
"russell2000": -1.152
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7744.06,
"base_price": 7718.94,
"return_since_base_pct": 0.3254,
"session_return_pct": 0.3254,
"as_of": "2026-10-15T20:13:48.969735Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29935.594,
"base_price": 29950.816,
"return_since_base_pct": -0.0508,
"session_return_pct": -0.0508,
"as_of": "2026-10-15T20:13:48.969735Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2767.85,
"base_price": 2729.5312,
"return_since_base_pct": 1.4039,
"session_return_pct": 1.4039,
"as_of": "2026-10-15T20:13:48.969735Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 8,
"timestamp": "2026-10-15T22:11:17.887017Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-15T22:11:17.887017Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.31,
"base_price": 6.245,
"return_since_base_pct": -14.972,
"session_return_pct": 2.71,
"change_since_prior_pct": -0.6548,
"volume_ratio": 1.08,
"rsi": 42.95,
"vwap": 5.31,
"vwap_distance_pct": 0.0,
"position_52w_pct": 59.0,
"extended_hours_pct": 0.0,
"as_of": "2026-10-15T20:01:27Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.52 > 5.54 > 5.15",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 2.3846,
"nasdaq100": 2.7608,
"russell2000": 1.3274
},
"price_as_of": "2026-10-15T20:01:27Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.0335,
"nasdaq100": 0.4097,
"russell2000": -1.0237
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.0642,
"nasdaq100": -3.688,
"russell2000": -5.1214
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.0735,
"nasdaq100": 0.3027,
"russell2000": -1.1307
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7744.06,
"base_price": 7718.94,
"return_since_base_pct": 0.3254,
"session_return_pct": 0.3254,
"as_of": "2026-10-15T22:08:16.381088Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29935.594,
"base_price": 29950.816,
"return_since_base_pct": -0.0508,
"session_return_pct": -0.0508,
"as_of": "2026-10-15T22:08:16.381088Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2767.2693,
"base_price": 2729.5312,
"return_since_base_pct": 1.3826,
"session_return_pct": 1.3826,
"as_of": "2026-10-15T22:08:16.381088Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 9,
"timestamp": "2026-10-16T14:22:44.863836Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-16T14:22:44.863836Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.14,
"base_price": 6.245,
"return_since_base_pct": -17.6942,
"session_return_pct": -3.2,
"change_since_prior_pct": -3.2015,
"volume_ratio": 0.17,
"rsi": 32.53,
"vwap": 5.19,
"vwap_distance_pct": -0.9634,
"position_52w_pct": 58.8,
"extended_hours_pct": null,
"as_of": "2026-10-16T14:06:07.820265Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.44 > 5.51 > 5.15",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-16T14:06:07.820265Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 9,
"timestamp": "2026-10-16T20:10:29.234467Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-16T20:10:29.234467Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.02,
"base_price": 6.245,
"return_since_base_pct": -19.6157,
"session_return_pct": -5.46,
"change_since_prior_pct": -2.3346,
"volume_ratio": 0.75,
"rsi": 31.23,
"vwap": 5.08,
"vwap_distance_pct": -1.1811,
"position_52w_pct": 57.4,
"extended_hours_pct": null,
"as_of": "2026-10-16T19:21:22.647785Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.42 > 5.5 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-16T19:21:22.647785Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 9,
"timestamp": "2026-10-16T22:05:48.128979Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-16T22:05:48.128979Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.0,
"base_price": 6.245,
"return_since_base_pct": -19.9359,
"session_return_pct": -5.84,
"change_since_prior_pct": -0.3984,
"volume_ratio": 0.98,
"rsi": 31.02,
"vwap": 5.08,
"vwap_distance_pct": -1.5748,
"position_52w_pct": 57.2,
"extended_hours_pct": 0.0,
"as_of": "2026-10-16T20:00:13Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.42 > 5.49 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-16T20:00:13Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 10,
"timestamp": "2026-10-19T20:01:23.798325Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-19T20:01:23.798325Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.115,
"base_price": 6.245,
"return_since_base_pct": -18.0945,
"session_return_pct": 2.3,
"change_since_prior_pct": 2.3,
"volume_ratio": 0.46,
"rsi": 36.19,
"vwap": 5.1,
"vwap_distance_pct": 0.2941,
"position_52w_pct": 58.5,
"extended_hours_pct": null,
"as_of": "2026-10-19T19:21:30.182691Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.36 > 5.46 > 5.14",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-19T19:21:30.182691Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 10,
"timestamp": "2026-10-19T22:18:42.737912Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-19T22:18:42.737912Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.03,
"base_price": 6.245,
"return_since_base_pct": -19.4556,
"session_return_pct": 0.6,
"change_since_prior_pct": -1.6618,
"volume_ratio": 0.83,
"rsi": 34.28,
"vwap": 5.1,
"vwap_distance_pct": -1.3725,
"position_52w_pct": 57.5,
"extended_hours_pct": 0.0,
"as_of": "2026-10-19T20:01:35Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.34 > 5.45 > 5.14",
"vwap_state": "above",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-19T20:01:35Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 11,
"timestamp": "2026-10-20T23:09:40.217030Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-20T23:09:40.217030Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.125,
"base_price": 6.245,
"return_since_base_pct": -17.9343,
"session_return_pct": 1.89,
"change_since_prior_pct": 1.8887,
"volume_ratio": 0.98,
"rsi": 37.97,
"vwap": 5.24,
"vwap_distance_pct": -2.1947,
"position_52w_pct": 60.1,
"extended_hours_pct": null,
"as_of": "2026-10-20T19:32:17.054310Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.3 > 5.42 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 1.606,
"nasdaq100": 2.0223,
"russell2000": 0.2362
},
"price_as_of": "2026-10-20T19:32:17.054310Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.0749,
"nasdaq100": 0.4912,
"russell2000": -1.2949
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.0228,
"nasdaq100": -3.6065,
"russell2000": -5.3926
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.0321,
"nasdaq100": 0.3842,
"russell2000": -1.4019
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7712.57,
"base_price": 7690.73,
"return_since_base_pct": 0.284,
"session_return_pct": 0.284,
"as_of": "2026-10-20T23:03:36.011816Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29490.283,
"base_price": 29529.344,
"return_since_base_pct": -0.1323,
"session_return_pct": -0.1323,
"as_of": "2026-10-20T23:03:36.011816Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2773.4197,
"base_price": 2728.298,
"return_since_base_pct": 1.6538,
"session_return_pct": 1.6538,
"as_of": "2026-10-20T23:03:36.011816Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 12,
"timestamp": "2026-10-21T00:35:47.988281Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-21T00:35:47.988281Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.09,
"base_price": 6.245,
"return_since_base_pct": -18.4948,
"session_return_pct": 1.79,
"change_since_prior_pct": -0.6829,
"volume_ratio": 1.18,
"rsi": 37.86,
"vwap": 5.24,
"vwap_distance_pct": -2.8626,
"position_52w_pct": 60.0,
"extended_hours_pct": -0.59,
"as_of": "2026-10-20T21:44:11Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.29 > 5.42 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": 1.506,
"nasdaq100": 1.9223,
"russell2000": 0.1362
},
"price_as_of": "2026-10-20T21:44:11Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": 0.0749,
"nasdaq100": 0.4912,
"russell2000": -1.2949
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.0228,
"nasdaq100": -3.6065,
"russell2000": -5.3926
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.0321,
"nasdaq100": 0.3842,
"russell2000": -1.4019
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7712.57,
"base_price": 7690.73,
"return_since_base_pct": 0.284,
"session_return_pct": 0.284,
"as_of": "2026-10-21T00:05:54.964695Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29490.283,
"base_price": 29529.344,
"return_since_base_pct": -0.1323,
"session_return_pct": -0.1323,
"as_of": "2026-10-21T00:05:54.964695Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2773.4197,
"base_price": 2728.298,
"return_since_base_pct": 1.6538,
"session_return_pct": 1.6538,
"as_of": "2026-10-21T00:05:54.964695Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 12,
"timestamp": "2026-10-21T21:52:26.689306Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-21T21:52:26.689306Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 5.13,
"base_price": 6.245,
"return_since_base_pct": -17.8543,
"session_return_pct": 0.2,
"change_since_prior_pct": 0.7859,
"volume_ratio": 0.43,
"rsi": 40.68,
"vwap": 5.17,
"vwap_distance_pct": -0.7737,
"position_52w_pct": 60.4,
"extended_hours_pct": 0.0,
"as_of": "2026-10-21T20:01:37Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.26 > 5.4 > 5.14",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"benchmark_excess_pct": {
"sp500": -0.3521,
"nasdaq100": -1.0661,
"russell2000": -0.149
},
"price_as_of": "2026-10-21T20:01:37Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"benchmark_excess_pct": {
"sp500": -0.1932,
"nasdaq100": -0.9072,
"russell2000": 0.0099
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"benchmark_excess_pct": {
"sp500": -4.2909,
"nasdaq100": -5.0049,
"russell2000": -4.0878
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"benchmark_excess_pct": {
"sp500": -0.3002,
"nasdaq100": -1.0142,
"russell2000": -0.0971
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [
{
"id": "sp500",
"symbol": "^GSPC",
"label": "S&P 500",
"role": "benchmark",
"price": 7755.15,
"base_price": 7712.57,
"return_since_base_pct": 0.5521,
"session_return_pct": 0.5521,
"as_of": "2026-10-21T16:43:22.625302Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "nasdaq100",
"symbol": "^NDX",
"label": "Nasdaq 100",
"role": "benchmark",
"price": 29863.658,
"base_price": 29490.283,
"return_since_base_pct": 1.2661,
"session_return_pct": 1.2661,
"as_of": "2026-10-21T16:43:22.625302Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
},
{
"id": "russell2000",
"symbol": "^RUT",
"label": "Russell 2000",
"role": "benchmark",
"price": 2783.0996,
"base_price": 2773.4197,
"return_since_base_pct": 0.349,
"session_return_pct": 0.349,
"as_of": "2026-10-21T16:43:22.625302Z",
"source": "yfinance.ticker_info",
"base_definition": "previous regular close"
}
],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 3
}
}
},
{
"day": 13,
"timestamp": "2026-10-22T19:35:28.462052Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-22T19:35:28.462052Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 4.82,
"base_price": 6.245,
"return_since_base_pct": -22.8183,
"session_return_pct": -6.04,
"change_since_prior_pct": -6.0429,
"volume_ratio": 0.67,
"rsi": 38.63,
"vwap": 4.94,
"vwap_distance_pct": -2.4291,
"position_52w_pct": 56.7,
"extended_hours_pct": null,
"as_of": "2026-10-22T19:21:50.306215Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.17 > 5.34 > 5.13",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"price_as_of": "2026-10-22T19:21:50.306215Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0
}
}
},
{
"day": 13,
"timestamp": "2026-10-22T22:04:24.148456Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-22T22:04:24.148456Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "n0:ALVO:2026-10-05:initial",
"decision_at": "2026-10-05T19:09:34.802136Z"
},
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 4.83,
"base_price": 6.245,
"return_since_base_pct": -22.6581,
"session_return_pct": -6.63,
"change_since_prior_pct": 0.2075,
"volume_ratio": 0.84,
"rsi": 38.21,
"vwap": 4.94,
"vwap_distance_pct": -2.2267,
"position_52w_pct": 56.4,
"extended_hours_pct": 0.89,
"as_of": "2026-10-22T20:23:11Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.17 > 5.34 > 5.12",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T15:18:33.137036+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-22T20:23:11Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:25+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:53+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0,
"day0_close_rows": 5,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
},
{
"day": 14,
"timestamp": "2026-10-23T14:55:57.805437Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-23T14:55:57.805437Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "n0:ALVO:2026-10-05:initial",
"decision_at": "2026-10-05T19:09:34.802136Z"
},
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 4.72,
"base_price": 6.245,
"return_since_base_pct": -24.4195,
"session_return_pct": -1.46,
"change_since_prior_pct": -2.2774,
"volume_ratio": 0.14,
"rsi": 18.55,
"vwap": 4.72,
"vwap_distance_pct": 0.0,
"position_52w_pct": 55.5,
"extended_hours_pct": null,
"as_of": "2026-10-23T14:06:04.621810Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.08 > 5.28 > 5.11",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T15:18:33.137036+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-23T14:06:04.621810Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:25+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:53+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0,
"day0_close_rows": 5,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
},
{
"day": 14,
"timestamp": "2026-10-23T19:53:17.209361Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-23T19:53:17.209361Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "n0:ALVO:2026-10-05:initial",
"decision_at": "2026-10-05T19:09:34.802136Z"
},
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 4.575,
"base_price": 6.245,
"return_since_base_pct": -26.7414,
"session_return_pct": -4.49,
"change_since_prior_pct": -3.072,
"volume_ratio": 0.45,
"rsi": 17.41,
"vwap": 4.66,
"vwap_distance_pct": -1.824,
"position_52w_pct": 53.8,
"extended_hours_pct": null,
"as_of": "2026-10-23T19:22:12.987963Z",
"source": "yfinance_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.05 > 5.27 > 5.1",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T15:18:33.137036+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-23T19:22:12.987963Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:25+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:53+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0,
"day0_close_rows": 5,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
},
{
"day": 14,
"timestamp": "2026-10-23T22:01:38.540034Z",
"comparison": {
"schema_version": "public-candidate-comparison.v1",
"captured_at": "2026-10-23T22:01:38.540034Z",
"base_definition": "Candidates use the publication reference; benchmarks use the previous regular close.",
"source": "sealed_update_market_context + canonical_candidate_snapshot + market_trajectory + public_market_snapshot",
"decision_reference": {
"decision_id": "n0:ALVO:2026-10-05:initial",
"decision_at": "2026-10-05T19:09:34.802136Z"
},
"rows": [
{
"symbol": "ALVO",
"role": "selected",
"price": 4.58,
"base_price": 6.245,
"return_since_base_pct": -26.6613,
"session_return_pct": -4.38,
"change_since_prior_pct": 0.1093,
"volume_ratio": 0.61,
"rsi": 17.45,
"vwap": 4.66,
"vwap_distance_pct": -1.7167,
"position_52w_pct": 53.9,
"extended_hours_pct": 0.0,
"as_of": "2026-10-23T20:01:27Z",
"source": "sealed_extended_quote",
"name": "Alvotech",
"episode_id": "n0:ALVO:2026-10-05",
"ema_trend": "5.05 > 5.27 > 5.1",
"vwap_state": "below",
"selection_as_of": "2026-10-05T15:18:33.137036Z",
"facts": [
"The sealed evidence reports FDA approval for added manufacturing capacity for SIMLANDI.",
"The captured move was +14.59% on 1.88x average volume; a later provider observation reports $6.135 and +12.568816%.",
"At the 15:18:30Z capture, the price was $6.24 and session VWAP was $6.25."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T15:18:33.137036+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-23T20:01:27Z",
"vwap_as_of": null
},
{
"symbol": "VST",
"role": "alternative",
"price": 145.41,
"base_price": 145.0475,
"return_since_base_pct": 0.2499,
"session_return_pct": 0.3589,
"change_since_prior_pct": 0.0,
"volume_ratio": 1.31,
"rsi": 58.95,
"vwap": 144.41,
"vwap_distance_pct": 0.6925,
"position_52w_pct": 67.01,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:33Z",
"source": "yfinance_quote",
"name": "Vistra Corp.",
"episode_id": "n0:VST:2026-10-05",
"ema_trend": "140.89 > 141.31 > 144.13",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:33Z",
"vwap_as_of": null
},
{
"symbol": "RRGB",
"role": "alternative",
"price": 8.05,
"base_price": 8.17,
"return_since_base_pct": -1.4688,
"session_return_pct": null,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"vwap": 7.96,
"vwap_distance_pct": 1.1307,
"position_52w_pct": 74.61,
"extended_hours_pct": null,
"as_of": "2026-10-05T20:15:00Z",
"source": "yfinance_quote",
"name": "Red Robin Gourmet Burgers, Inc.",
"episode_id": "narrative:RRGB:c4bd3a73f5c8befa",
"ema_trend": "7.72 > 7.81 > 7.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:25Z",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:25+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T20:15:00Z",
"vwap_as_of": null
},
{
"symbol": "PCVX",
"role": "alternative",
"price": 71.06,
"base_price": 73.55,
"return_since_base_pct": -3.3855,
"session_return_pct": -3.7388,
"change_since_prior_pct": 0.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"vwap": 80.09,
"vwap_distance_pct": -11.2748,
"position_52w_pct": 81.21,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:19:53Z",
"source": "yfinance_quote",
"name": "Vaxcyte, Inc.",
"episode_id": "narrative:PCVX:05066bc6940d4242",
"ema_trend": "60.42 > 59.46 > 58.94",
"vwap_state": "below",
"selection_as_of": "2026-10-05T17:20:09Z",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:20:09+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:19:53Z",
"vwap_as_of": null
},
{
"symbol": "LLY",
"role": "alternative",
"price": 1146.0,
"base_price": 1154.4901,
"return_since_base_pct": -0.7354,
"session_return_pct": 0.2519,
"change_since_prior_pct": 0.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"vwap": 1152.11,
"vwap_distance_pct": -0.5303,
"position_52w_pct": 89.42,
"extended_hours_pct": null,
"as_of": "2026-10-05T21:07:21Z",
"source": "yfinance_quote",
"name": "Eli Lilly and Company",
"episode_id": "narrative:LLY:453fbf0f479bbb5d",
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"vwap_state": "above",
"selection_as_of": "2026-10-05T17:19:53Z",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"day0_close": {
"status": "missing",
"market_day": "2026-10-05",
"reference_as_of": "2026-10-05T17:19:53+00:00",
"reason": "same_day_regular_close_not_captured",
"price": null,
"base_price": null,
"return_since_base_pct": null,
"as_of": "",
"available_at": "",
"source": "",
"capture_kind": "",
"source_fields_sha256": "",
"benchmark_status": "unavailable",
"benchmarks": []
},
"price_as_of": "2026-10-05T21:07:21Z",
"vwap_as_of": null
}
],
"benchmarks": [],
"coverage": {
"candidate_rows": 5,
"candidate_prices": 5,
"candidate_technical": 5,
"benchmark_rows": 0,
"day0_close_rows": 5,
"day0_close_prices": 0,
"day0_close_benchmark_rows": 0
}
}
}
],
"candidates": [
{
"symbol": "VST",
"name": "Vistra Corp.",
"exchange": "NYSE",
"tradingview_url": "https://es.tradingview.com/chart/?symbol=NYSE%3AVST&interval=60",
"score": null,
"price": 145.0475,
"change": null,
"volume": 6011492,
"avg_volume_3m": 4600342,
"volume_ratio": 1.31,
"rsi": 58.95,
"ema_trend": "140.89 > 141.31 > 144.13",
"position_52w_pct": 67.01,
"vwap": 144.41,
"vwap_distance_pct": null,
"vwap_state": "above",
"facts": [
"The captured change was +3.90% with a 1.32x volume ratio.",
"The catalyst describes expectations for federal financing."
],
"role": "alternative",
"selected": false,
"reason": "strong_alternative_not_selected"
},
{
"symbol": "RRGB",
"name": "Red Robin Gourmet Burgers, Inc.",
"exchange": "NASDAQ",
"tradingview_url": "https://es.tradingview.com/chart/?symbol=NASDAQ%3ARRGB&interval=60",
"score": null,
"price": 8.17,
"change": null,
"volume": 167653.0,
"avg_volume_3m": 288179.0,
"volume_ratio": 0.58,
"rsi": 66.43,
"ema_trend": "7.72 > 7.81 > 7.94",
"position_52w_pct": 74.61,
"vwap": 7.96,
"vwap_distance_pct": null,
"vwap_state": "above",
"facts": [
"The issuer announcement and SEC 8-K report completion of refinancing.",
"The captured change was +2.77% on 0.58x average volume."
],
"role": "alternative",
"selected": false,
"reason": "strong_alternative_not_selected"
},
{
"symbol": "PCVX",
"name": "Vaxcyte, Inc.",
"exchange": "NASDAQ",
"tradingview_url": "https://es.tradingview.com/chart/?symbol=NASDAQ%3APCVX&interval=60",
"score": null,
"price": 73.55,
"change": null,
"volume": 10349182.0,
"avg_volume_3m": 1154593.0,
"volume_ratio": 8.98,
"rsi": 73.26,
"ema_trend": "60.42 > 59.46 > 58.94",
"position_52w_pct": 81.21,
"vwap": 80.09,
"vwap_distance_pct": null,
"vwap_state": "below",
"facts": [
"The packet reports positive OPUS-1 Phase 3 results; an SEC 8-K is listed, but its contents are not excerpted.",
"The captured change was +30.48% on 8.98x average volume.",
"At the 13:22 ET capture, price was $73.69 versus session VWAP of $80.09. VWAP means the session’s average trading price weighted by volume."
],
"role": "alternative",
"selected": false,
"reason": "strong_alternative_not_selected"
},
{
"symbol": "LLY",
"name": "Eli Lilly and Company",
"exchange": "NYSE",
"tradingview_url": "https://es.tradingview.com/chart/?symbol=NYSE%3ALLY&interval=60",
"score": null,
"price": 1154.4901,
"change": null,
"volume": 845981.0,
"avg_volume_3m": 2496209.0,
"volume_ratio": 0.34,
"rsi": 56.97,
"ema_trend": "1159.36 > 1161.71 > 1168.94",
"position_52w_pct": 89.42,
"vwap": 1152.11,
"vwap_distance_pct": null,
"vwap_state": "above",
"facts": [
"Trusted reporting describes FDA label expansion for Jaypirca.",
"The captured change was +1.14% on 0.34x average volume."
],
"role": "alternative",
"selected": false,
"reason": "strong_alternative_not_selected"
}
],
"news": [
{
"title": "SEC 6-K filing",
"url": "https://www.sec.gov/Archives/edgar/data/1898416/000117184326006383/f6k_100526.htm"
}
],
"transcript_url": null,
"initial_transcript_anchor": "transcript-entry-a629da5e53498574501ef110d1a0fccfef1c752342ff319807f3a6dcc4ab9cf7",
"chart_url": null,
"secondary_chart_url": null,
"forecast_chart_url": null,
"methodology_url": "https://trydingday.com/methodology/",
"track_record_url": "https://trydingday.com/track-record/",
"market_timezone": "America/New_York"
}
}